Conn, D. L. The story behind the use of glucocorticoids in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 51, 15–19 (2021).

Article  CAS  PubMed  Google Scholar 

Cain, D. W. & Cidlowski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 233–247 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

McLornan, D. P., Pope, J. E., Gotlib, J. & Harrison, C. N. Current and future status of JAK inhibitors. Lancet 398, 803–816 (2021).

Article  PubMed  Google Scholar 

O’Shea, J. J. & Gadina, M. Selective Janus kinase inhibitors come of age. Nat. Rev. Rheumatol. 15, 74–75 (2019).

Article  PubMed  Google Scholar 

Liu, C., Kieltyka, J., Fleischmann, R., Gadina, M. & O’Shea, J. J. A decade of JAK inhibitors: what have we learned and what may be the future? Arthritis Rheumatol. 73, 2166–2178 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shuai, K. & Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3, 900–911 (2003).

Article  CAS  PubMed  Google Scholar 

Strobl, B., Stoiber, D., Sexl, V. & Mueller, M. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front. Biosci. 16, 3214–3232 (2011).

Article  Google Scholar 

Burke, J. R. et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci. Transl. Med. 11 (2019).

Fuchs, S. et al. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur. J. Immunol. 46, 2639–2649 (2016).

Article  CAS  PubMed  Google Scholar 

Teng, M. W. et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719–729 (2015).

Article  CAS  PubMed  Google Scholar 

Yang, K., Oak, A. S. W. & Elewski, B. E. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am. J. Clin. Dermatol. 22, 173–192 (2021).

Article  PubMed  Google Scholar 

Singh, J. A. et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 71, 5–32 (2019).

Article  PubMed  Google Scholar 

Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann. Rheum. Dis. 79, 700–712 (2020).

Article  PubMed  Google Scholar 

Menter, A. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 80, 1029–1072 (2019).

Article  PubMed  Google Scholar 

Sarabia, S., Ranjith, B., Koppikar, S. & Wijeratne, D. T. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol. 6, 71 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211–221 (2020).

Article  CAS  PubMed  Google Scholar 

Furie, R. A. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, e208–e219 (2019).

Article  PubMed  Google Scholar 

Kalunian, K. C. et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 75, 253–265 (2023).

Article  CAS  PubMed  Google Scholar 

Hagberg, N. et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE. Ann. Rheum. Dis. 77, 1070–1077 (2018).

Article  CAS  PubMed  Google Scholar 

Parkes, M., Cortes, A., van Heel, D. A. & Brown, M. A. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 14, 661–673 (2013).

Article  CAS  PubMed  Google Scholar 

Sigurdsson, S. et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76, 528–537 (2005).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cunninghame Graham, D. S. et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 7, e1002341 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin, Q. et al. Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis. Arch. Dermatol. Res. 310, 711–728 (2018).

Article  CAS  PubMed  Google Scholar 

Diogo, D. et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS One 10, e0122271 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Lopez-Isac, E. et al. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. Ann. Rheum. Dis. 75, 1521–1526 (2016).

Article  CAS  PubMed  Google Scholar 

Bossini-Castillo, L. et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum. Mol. Genet. 21, 926–933 (2012).

Article  CAS  PubMed  Google Scholar 

Hu, L. et al. Interleukin-22 from type 3 innate lymphoid cells aggravates lupus nephritis by promoting macrophage infiltration in lupus-prone mice. Front. Immunol. 12, 584414 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang, X. et al. Increased interleukin-22 levels in lupus nephritis and its associated with disease severity: a study in both patients and lupus-like mice model. Clin. Exp. Rheumatol. 37, 400–407 (2018).

PubMed  Google Scholar 

Jani, M. et al. Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. Ann. Rheum. Dis. 73, 1750–1752 (2014).

Article  PubMed  Google Scholar 

Hromadova, D., Elewaut, D., Inman, R. D., Strobl, B. & Gracey, E. From science to success? targeting tyrosine kinase 2 in spondyloarthritis and related chronic inflammatory diseases. Front. Genet. 12, 685280 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takeda. Takeda announces positive results in phase 2b study of investigational TAK-279, an oral, once-daily TYK2 inhibitor, in people with moderate-to-severe plaque psoriasis [press release]. Takeda.com https://www.takeda.com/newsroom/newsreleases/2023/takeda-announces-positive-results-in-phase-2b-study-of-investigational-tak-279/ (2023).

Papp, K. et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N. Engl. J. Med. 379, 1313–1321 (2018).

Article  CAS  PubMed  Google Scholar 

Armstrong, A. W. et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J. Am. Acad. Dermatol. 88, 29–39 (2023).

Article  CAS  PubMed  Google Scholar 

Strober, B. et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial. J. Am. Acad. Dermatol. 88, 40–51 (2023).

Article  CAS  PubMed  Google Scholar 

Mease, P. J. et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann. Rheum. Dis. 81, 815–822 (2022).

Article  CAS  PubMed  Google Scholar 

Felson, D. T. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheumatol. 38, 727–735 (1995).

Article  CAS  Google Scholar 

Furie, R. A. et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheumatol. 61, 1143–1151 (2009).

Article  CAS  Google Scholar 

Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 75, 242–252 (2023).

Article  CAS  PubMed  Google Scholar 

Connelly, K., Golder, V., Kandane-Rathnayake, R. & Morand, E. F. Clinician-reported outcome measures in lupus trials: a problem worth solving. Lancet Rheumatol. 3, e595–e603 (2021).

Article  CAS  PubMed  Google Scholar 

Wu, C. et al. Pharmacodynamic changes in SLE relevant gene expression induced by deucravacitinib in patients enrolled in the phase 2. Arthritis Rheumatol. 75